First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Shares Down 1.7% – Time to Sell?

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)’s stock price was down 1.7% on Thursday . The stock traded as low as $33.95 and last traded at $34.00. Approximately 1,467 shares traded hands during trading, a decline of 81% from the average daily volume of 7,671 shares. The stock had previously closed at $34.59.

First Trust Nasdaq Pharmaceuticals ETF Stock Down 1.7%

The firm’s fifty day moving average price is $34.14 and its 200 day moving average price is $33.25. The stock has a market cap of $30.60 million, a PE ratio of 14.51 and a beta of 0.47.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Thursday, March 26th were issued a $0.0573 dividend. This represents a $0.23 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Thursday, March 26th.

Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Several hedge funds have recently modified their holdings of the stock. LPL Financial LLC lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 40.5% in the fourth quarter. LPL Financial LLC now owns 146,105 shares of the company’s stock worth $4,813,000 after buying an additional 42,147 shares in the last quarter. Marshall Investment Management LLC purchased a new position in shares of First Trust Nasdaq Pharmaceuticals ETF in the fourth quarter worth $1,377,000. Goldman Sachs Group Inc. lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 11.7% in the first quarter. Goldman Sachs Group Inc. now owns 19,472 shares of the company’s stock worth $535,000 after buying an additional 2,047 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 2.1% in the third quarter. Envestnet Asset Management Inc. now owns 18,132 shares of the company’s stock worth $517,000 after buying an additional 367 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 9.7% in the third quarter. Ameritas Investment Partners Inc. now owns 17,232 shares of the company’s stock worth $491,000 after buying an additional 1,521 shares in the last quarter.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.